>>18748871 lb
>Donald Trump floats that Tucker Carlson left Fox because he wanted 'free rein'
Hostage no more?
>'free rein'
Free Rain
April Showers
1257
Apr 24,2018 11:42:14 AM EDT
Q !xowAT4Z3VQ ID: bc4b43 No. 1169294
Apr 24, 2018 11:37:59 AM EDT
Q !xowAT4Z3VQ ID: bc4b43 No. 1169241
Apr 24, 2018 11:30:18 AM EDT
Q !xowAT4Z3VQ ID: bc4b43 No. 1169138
>>1169112
His sole purpose [WH visit] is to convince POTUS, on behalf of the EU, to remain in the Iran deal.
You decide.
Q
>>1169138
What’s at risk?
$250B x 2 / year.
What the taxpayers don’t know.
Why aren’t NK developments receiving WW praise?
We endure.
Q
>>1169241
HOSTAGE NO MORE.
Q
1146
Apr 14, 2018 2:24:45PM EDT
Q !xowAT4Z3VQ ID: 072bee No. 1041555
901FFF2C-CFFC-4586-8226-7….jpeg
Expand your thinking.
The ‘date’ vs ‘actual’.
Iran next.
Trust the plan!
APRIL SHOWERS.
[SHOWERS].
Do you believe in coincidences?
Q
>Hunter Biden hides away at Joe Kiani’s
>$50M California vineyard amid his brewing
>criminal probes:
Joe Kiani
Iranian
Covid Med tech Billionaire
'Meet The Iranian Immigrant Who Became A Covid MedTech Billionaire
Oct 3, 2022,07:21am EDT
Joe Kiani surmounted overwhelming personal and professional odds to build a better blood oxygen monitoring device. So why should he be afraid to push his scrappy company into consumer electronics, challenging firms 100 times its size?
J
oe Kiani had achieved the dream. Masimo Corp., which he founded and runs as CEO and chairman, had carved out a lucrative niche as one of the top makers of pulse oximeters, those fingertip sensors that hospitals use to measure oxygen saturation in patients’ blood. Masimo had made Kiani, who immigrated in poverty to the U.S. from Iran as a child, rich—a billionaire, by Forbes’ reckoning. As an electrical engineer, he took pride in the fact that devices he had personally designed were excellent, commanding a slightly bigger share of the U.S. hospital pulse oximeter market than its chief competitor, Nellcor, which is a unit of Medtronic, a company roughly 15 times Masimo’s size. Together the two companies account for about 90% of sales.
It’s a profitable enterprise, too—last year Masimo, based in Irvine, California, earned $223 million on $1.2 billion in revenue. Amid a rising stock market and bolstered by increased demand for Masimo’s technology due to Covid-19 (low blood oxygen levels being an early warning that the disease is getting worse), the company’s shares climbed 85% from early 2020 through the end of 2021, giving Masimo a market capitalization of more than $16 billion.
Then Kiani decided to complicate the dream. After the market closed this February 15, Masimo announced it was spending just over $1 billion to buy Sound United, a consumer-focused audio, speaker and headphone business that owns brands such as Marantz, Denon, Bowers & Wilkins and Boston Acoustics. The next day, Masimo’s stock plunged 37%, wiping out $5 billion in market value.
Kiani was shocked. “We thought [investors] would say ‘awesome!’ And given our track record, we’re not going to screw it up,” he declares, perched on an ecru couch in his compulsively neat office. “You know what one of them said to me? Very angry shareholder, big shareholder? ‘Give it back. Don’t buy it.’”
But Mike Polark, an analyst at Wolfe Research in Boston, wasn’t surprised at the negative reaction: “In medtech, focus pays.” At eight times Ebitda, the problem wasn’t that Kiani had overpaid for Sound United. It’s also a healthy, profitable business expected to bring Masimo’s revenue to $2 billion this year, a 67% increase. “The issue for Wall Street is strategic direction,” Polark continues. “Why is Masimo selling over-the-ear headphones?”
The acquisition would instantly render Kiani’s company less profitable. The gross margin on Masimo’s medical device business had been a lofty 65.8%. In commodity consumer electronics, like headphones, 20% is more typical.
The move prompted activist investor Politan Capital Management, a year-old firm led by Quentin Koffey—a veteran of activist investor Paul Singer’s Elliott Management and hedge fund D.E. Shaw—to acquire a nearly 9% stake in Masimo, according to an early August filing. Politan would not comment on its plans, but back in March the firm helped push health insurance firm Centene to replace its CEO.
https://www.forbes.com/sites/kerryadolan/2022/10/03/meet-the-iranian-immigrant-who-became-a-covid-medtech-billionaire/?sh=77ab15a82abc